What is the ABVD chemotherapy regimen?

Hello,

Welcome to icliniq.com.

I can understand your concern.

I have gone through your medical history carefully and am sorry for the health problems you are going through. Good news, you finally got your diagnosis and treatment.

Hodgkin lymphoma is defined by Reed–Sternberg cells (cHL). Often, it spreads in a more predictable, “contiguous” pattern from one lymph node region to the next. I have very high cure rates even when advanced, because it is highly chemo-sensitive. Non-Hodgkin lymphoma (NHL) involves a large family of many different lymphomas (B-cell and T-cell types).

Their behavior varies widely. Some are slow-growing (indolent), others are aggressive. Regarding the treatment and prognosis, they depend strongly on the specific subtype (e.g., follicular and mantle cell, etc.).

There is no clear cause. All we know is that it can arise from abnormal B-cells plus immune signaling in the lymph node environment.

Currently, you are stage III cHL, which is serious and needs quick systemic therapy, but it is still considered curable.

ABVD chemotherapy regimen is the classical treatment in cHL, and its formula consists of: A = Adriamycin (Doxorubicin), B = Bleomycin, V = Vinblastine, D = Dacarbazine. It is typically given in cycles, commonly with treatment days on day one and day 15 of each cycle (your oncologist will give the exact schedule they particularly use).

Interim PET (positron emission tomography) or CT (computed tomography) after two cycles is commonly used in many approaches to guide whether bleomycin is continued or modified (PET-adapted strategy).

Many patients with stage III treated with effective systemic therapy do not need radiation, particularly if PET shows a strong complete metabolic response. Decisions are individualized and often PET-driven.

Side effects you may feel during treatment include fatigue, nausea/vomiting, changes in appetite or taste, hair thinning/loss, mouth sores, constipation, low blood counts, which puts you at risk for infection, anemia or bruising.

There are other drug-specific risks:

1. Bleomycin: Lung inflammation or scarring risk (pulmonary toxicity).

2. Doxorubicin (Adriamycin): Heart toxicity risk at higher cumulative doses.

3. Vinblastine: Neuropathy, tingling, and constipation.

4. Dacarbazine: It causes nausea. If radiation is used, later risks depend on the field (thyroid issues, secondary cancers, heart and lung effects when the chest is irradiated). Your healthcare team will balance these carefully.

ABVD is generally considered less gonadotoxic than many other regimens, but the fertility impact is not zero, and risk varies with age and baseline fertility. So, before undergoing any treatment, and if having children matters to you, you should ask immediately for a fertility preservation referral.

Within the first couple of years, patients can relapse; however, even if they return, there are still options for treatment, including salvage chemotherapy, high-dose therapy with autologous stem cell transplant in appropriate candidates, and targeted therapy (e.g., Brentuximab vedotin) or immunotherapy (PD-1 inhibitors), depending on prior treatment and response. Relapse is not the end of the road; there are strong second-line pathways to manage and cure it.

I hope this information will help you.

Thanks.